Helixmith Co Ltd
KOSDAQ:084990
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (55.5), the stock would be worth ₩3 129.67 (65% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 158.6 | ₩8 950 |
0%
|
| 3-Year Average | 55.5 | ₩3 129.67 |
-65%
|
| 5-Year Average | 88.6 | ₩5 000.69 |
-44%
|
| Industry Average | 17.7 | ₩997.21 |
-89%
|
| Country Average | 1 | ₩59.17 |
-99%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
Helixmith Co Ltd
KOSDAQ:084990
|
412.1B KRW | 158.6 | -947.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 5.7 | 83.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.4 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 9.1 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 5.4 | 17.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 11.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 2.7 | 30.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.5 |
| Median | 1 |
| 70th Percentile | 2.4 |
| Max | 101 134.7 |
Other Multiples
Helixmith Co Ltd
Glance View
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
